Tissue engineering (TE) has existed for several years as an area spanning many disciplines, including medicine and engineering. The use of stem cells as a biological basis for TE coupled with advances in materials science has opened up an entirely new chapter in medicine and holds the promise of major contributions to the repair, replacement and regeneration of damaged tissues and organs. In this article, we review the spectrum of stem cells and scaffolds being investigated for their potential applications in medicine.
Tissue engineering (TE) is focusing on the creation of biohybrid organs TE has emerged as a thriving new field of medical science. Just a few years ago, most scientists believed that human tissue could be replaced only with direct transplants or full artificial parts made of plastic, metal and/or computer chips. Now, scientists are focusing on the creation of biohybrid organs. TE is best defined by its goal: the design and construction in the laboratory of living, functional components that can be used for the maintenance, regeneration or replacement of malfunctioning tissues. It is multidisciplinary, requiring expertise from a wide range of fields including cell biology, material sciences, engineering, physics and mathematics.
An alternative to organ replacement is the prospect of in vivo repair or regeneration. Newts, tadpoles and
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Tissue engineering is focusing on the creation of biohybrid organs. Primary adult and foetal cells can be used for tissue engineering. Stem cells provide many advantages over mature cells. Embryonic stem cells are the source of all tissue types. Adult or somatic stem cells are less plastic than embryonic stem cells but may be more appropriate for treating some conditions. Stem cells have great potential as therapeutic agents and are already being used to repair tissues. Developments in materials science are providing new opportunities for tissue regeneration. Bioceramics provide an ideal scaffold for engineering of bone. A variety of materials for tissue engineering scaffolds have been assessed. Clinical application of tissue engineering strategies needs to meet a variety of challenges. New techniques have been developed that test the efficacy of engineered tissues in vitro.
Prospects
New and more efficient means to control stem cell differentiation will emerge. Many stem cell therapies currently at a basic stage or being tested for safety and efficacy in animal models will move rapidly, although to testing in humans where robust, randomized clinical trials must be carried out. Understanding of mechanisms of cell engraftment into a host tissue. Expansion of clonally differentiated stem cells into a cost-efficient, scalable process guaranteeing product reproducibility/viability and satisfying regulations. For this, growth of cells in bioreactors (growth chambers equipped with stirrers and sensors) that regulate the appropriate amounts of nutrients, gases and waste products will be needed. Design of man-made materials that support and coordinate the growth of three-dimensional tissues in the laboratory. Design of appropriate delivery systems. Design of strategies to overcome immunological challenges and deal with regulatory and safety issues.
zebrafish easily repair and regenerate damaged organs. Research is being undertaken to study how such regeneration is achieved and how we can harness the body's innate capacity for such functions. Perhaps, only a small number of adult stem cells are needed to stimulate the regenerative body responses, provided that cells home to sites of injury and promote healing in damaged tissues.
Primary adult and foetal cells can be used for TE
A variety of cells has been used for TE. Initial work used fully mature cells taken from adult tissue but, although these have certain advantages including the possibility of using autologous cells to avoid immunological problems, they have low growth potential and a relatively high degree of senescence. However, we and others have demonstrated the ability of, for example, adult human bone cells to attach, grow and differentiate when in contact with specific man-made materials, such as Bioglass.
1,2 Fully committed cells from foetal tissue (7-10 weeks gestation) have also been used and shown to be a good source for TE. These cells have much greater proliferative capacity and show less senescence than adult cells. 3, 4 Stem cells provide many advantages over mature cells A stem cell is defined by three main criteria: self-renewal, ability to differentiate into multiple cell types and capability of in vivo reconstitution of a given tissue. The most primitive is the fertilized oocyte (the zygote) ( Figure 1 ). Once the fertilized egg starts dividing, the descendants of the first two divisions are the totipotent cells able to form the embryo and trophoblast. After about 4 days, these totipotent cells form a hollow ball of cells, the blastocyst, containing a cluster of cells called the inner cell mass from which the embryo develops and embryonic stem (ES) cells are derived.
Lower down in the hierarchical tree are the multipotent cells. Most adult tissues have multipotent stem cells that can produce a limited range of differentiated cell lineages appropriate to their location. At the bottom of the hierarchical tree are the unipotent stem cells, or committed progenitors, that generate one specific cell type.
Current sources of stem cells for TE include ES cells and adult stem cells. However, concerns exist over the use in TE of either source: for ES cells, there are ethical considerations, the potential for tumorigenicity and a current paucity of cell lines, while adult stem cells are more limited in potential and often difficult to harvest in sufficient numbers. Thus, the search continues for an ethically conducive, easily accessible and abundant source of stem cells.
ES cells are the source of all tissue types
Pluripotent stem cells can be divided into three different types: embryonic germ (EG) derived from primordial germ cells, ES cells and embryonic carcinoma (EC) cells. These cells are widely held to be pluripotent, that is, able to differentiate into all cells that arise from the three germ layers but not the embryo.
The intellectual framework that led to the isolation and derivation of ES cells began in the 1970s when investigators discovered pluripotent cells in teratocarcinomas. Murine ES cells where isolated in the 1980s by two major workers, Evans and Kaufman (Figure 2 ). After 17 years, ES cells were isolated successfully from human blastocysts. Following multiple passages of ES cell cultures, genetic and epigenetic changes can occur. 5 A unique network of transcription factors ensures self- Progress and prospects in tissue engineering J Polak and L Hench renewal and simultaneously suppresses differentiation of ES cells. These include Nanog, octa-binding factor 3/4 (OCT4) and Wnt. Nanog was discovered by expression cloning analysis and named after the mythological Celtic land of the ever young, Tir nan Og. 6 Oct4 is a member of the Pit-Oct-Unc (POU) family of transcriptional regulators restricted to early embryos. 7 The Wnt family consists of secreted and extracellular matrix (ECM)-associated glycoproteins binding to frizzled seven-transmembrane span receptors. 8 Recently, global transcription factors for human ES cells were identified using DNA microarray 9, 10 SAGE 11 and cDNA library analysis. 12 All demonstrated the existence of gene clusters that are expressed at signicantly higher levels in human ES cells compared with fully differentiated cells. Human ES cells are characterized by their expression of SSEA3, SSEA4, TRA-1-60 and TRA-1-81 antigens that are now known to be downregulated during differentiation while several other antigens are induced. 12 In preparation for the clinical application of human ES cells, efforts are being made increasingly to (a) define the culture media/conditions needed to derive specific cell phenotypes and their progenitors and (b) use cultures free of contamination with animal proteins. Questions that need to be addressed before human ES cells can be used clinically include:
(a) Can pure populations of cells be derived in sufficient numbers for implantation? (b) Can the necessary requirements of 'good medical practice' be achieved (ie xeno-free)? (c) How can potential problems of tissue rejection be resolved?
Regarding the last question, undifferentiated mesenchymal stem cells (MSC) do not express immunologically relevant cell surface markers and, as such, appear to be immunoprivileged. 13 For ES cells, a stem cell bank has already been established by the Medical Research Council in the UK, which will provide a variety of cell lines to match the immune requirements of patient. Somatic cell nuclear transfer (SCNT) is another method that can provide immunocompatible cells. SCNT, or therapeutic cloning, that has recently been used to generate animals with a common genetic composition, comprises the transfer of the nucleus of a somatic cell, for example, from a patient needing TE, into an enucleated donor oocyte. Subsequently, ES cells can be isolated from the inner cell mass of the cloned preimplantation embryo that carry the genome of the patient and, upon implantation, the cells will not be rejected. Korean workers recently reported the successful isolation of human ES cells by this method. 14, 15 Politics, religious belief and the media have determined society's current perception of the value and medical potential of ES cells. The ethical antipathy towards ES cells, which require the destruction of human embryos for their derivation, has biased research towards adult stem cells in some countries. The situation in the UK is that the Human Embryology & Fertilization Authority has given authorization to use and, in some cases, create human embryos for therapeutic purposes. Research into adult and ES cells is not sufficiently advanced for a definitive and exclusive choice to be made on whether one type is better or worse than the other as a basis for developing a broad range of stem cell therapies. Each is likely to have its own niche in therapy or, for some conditions, a combination both of adult and ES cells may prove best.
A variety of protocols has proved useful in driving the differentiation of ES cells to particular lineages, including the use of growth factor supplementation of media and genetic modification. In our own laboratories, a robust system has been developed for osteoblast and pneumocyte ( Figure 3 ) differentiation from murine and human ES cells using a defined culture medium. [16] [17] [18] Recent technological advances, such as RNA interference to knock down gene expression in ES cells, are also producing enriched populations and elucidating gene function in early development. [19] [20] [21] The success of stem cell transplantation depends on the ability of cells to interact with stromal cells and repopulate the corresponding niches, a property of stem cells known as homing. The mechanisms regulating homing are not fully understood but signalling molecules such as chemokines and growth factors are involved and the expression of these increases following tissue injury. Using the property of mammalian cells to adapt and remodel in response to physiological/environmental cues, coculture of embryonic and other stem/ progenitor cells with mature cells or tissues is being used increasingly to drive their differentiation towards required lineages. 22, 23 Our recent work showed that coculture with murine embryonic pulmonary mesenchyme is an efficient means to upregulate the differentiation of ES cells towards pneumocytes. 24 Adult or somatic stem cells are less plastic than ES cells but may be more appropriate for treating some conditions Progress and prospects in tissue engineering J Polak and L Hench of origin but not cells of unrelated tissues. The first evidence of 'plasticity' or 'transdifferentiation' stemmed from the observation that, following gender mismatched bone marrow transplants, some donor cells could be found in multiple organs in the recipient, having adopted the characteristics of cells of the organ in which they had lodged. Various reports over the last 6 years challenged this dogma by demonstrating that adult stem cells, under certain microenvironmental conditions, give rise to other cell types besides the original cell type, indicating that they can switch cell fate. This phenomenon has been termed 'stem cell plasticity'. However, subsequent reports have generated both excitement as well as scepticism. 23, 24 The concept of plasticity defies the basic developmental biology principle of lineage restriction being imparted during morphogenesis but, if correct, the ability of adult stem cells to change fate holds immense therapeutic potential. It is important, therefore, that the concept of stem cell plasticity be rigorously defined and experimentally proven. To achieve this, the following criteria need to be met. 
Bone marrow stem cells
The most studied adult stem cell, the haematopoietic stem cell (HSC), resides in the bone marrow. 28 More recently, a common cell origin for haematopoietic cells and osteoblasts has been demonstrated in the bone marrow. 29 More research needs to be carried out to assess the relationship between MAPCs to MSCs.
There is some evidence in animal models that bone marrow stem cells can engraft in the lung and differentiate to pulmonary alveolar epithelium where they can repair injury. For the human lung, chimerism has been demonstrated in human pulmonary epithelium, including that of the alveoli, following transplantation of HSCs 30, 31 and lung 32 without evidence for engraftment of cells from the bone marrow. However, we have recently challenged the above by demonstrating bone marrow origin of engrafted cells in the injured lung of female patients who had received a male bone marrow transplant. 33 MSC are clonogenic, nonhaematopoietic cells present in the bone marrow that can differentiate into multiple mesoderm-type cell lineages, for example, osteoblasts, chondrocytes, endothelial cells and also nonmesodermal lineages, for example, neuronal-like cells. Under current in vitro culture conditions that include foetal bovine serum, MSC obtained from young donors can grow to 24-40 population doublings in vitro, while the proliferative potential of MSC obtained from older donors is more compromised. 34 As it is older individuals that are most likely to require TE, this senescence reduces the applicability of autologous MSC in tissue repair strategies.
Niche-specific stem cells
Adult tissues undergo continuous self-renewal and, hence, require resident stem cells with the capacity for multipotent differentiation. These stem cells are most often slow-cycling and give rise to transient amplifying cells, which impart the majority of tissue renewal in the setting of injury. Unlike stem cells, which by definition have unlimited proliferative capacity, transient amplifying cells are restricted in their capacity to divide and cannot proliferate indefinitely. Although stem cells and transient amplifying cells are both self-renewing populations, the latter are thought primarily to be the major progenitor population, which gives rise to terminally differentiated cell types of an adult organ.
Four areas for potential clinical use of MSCs have been explored: local implantation for localized diseases, systemic transplantation, combining stem cell therapy with gene therapy and use in TE protocols.
Other sources of stem cells
Many authors have recently reported the differentiation of stem cells from other sites into multiple cell lineages and newly identified sources include fat, 35 placenta 36 and spleen. 37 Such sites can be an abundant source of stem cells; for example, a single gram of human adipose tissue 
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Stem cells have great potential as therapeutic agents and are already being used to repair tissues
Numerous studies have recently demonstrated successful restoration of lost organ function by the use of a variety of stem cells of different origins. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] For example, several recent studies have highlighted the successful treatment of acute myocardial infarction by injection of autologous bone marrow cells. [48] [49] [50] Developments in materials science are proving new opportunities for tissue regeneration TE scaffolds have a dual purpose: to direct morphogenesis in vitro and maintain the structure and function of the TE construct as it is integrated with the host tissues postimplantation. 51, 52 An ideal scaffold for TE and regeneration 1. is made from a material that is biocompatible, that is, not cytotoxic; 2. acts as template for tissue growth in three dimensions; for example, collagen is organized parallel to the surface in articular cartilage and perpendicular to the surface in the osteochondral region of an articulating join; 3. has an interconnected macroporous network with pore diameters in excess of 100 mm for cell penetration, tissue ingrowth, vascularization and nutrient delivery throughout the regenerating tissue; 4. bonds to host tissue without formation of intervening scar tissue; 5. exhibits a surface texture and chemistry that promotes cell adhesion, adsorption of biological metabolites, including growth factors; 6. influences the genes in stem cells to enhance differentiation and proliferation of all the phenotypes required for tissue regeneration while not altering clonogenic or proliferative potential of the cells; 7. resorbs at the same rate as the tissue is repaired, with degradation products that are nontoxic and can be easily excreted; 8. can be produced in irregular shapes to match the tissue defect; 9. has mechanical properties sufficient to withstand applied stresses in clinical applications; 10. has the potential to be commercially produced to the required ISO (International Standards Organisation) and FDA (Food and Drug Administration) regulatory standards at a cost suitable for routine clinical use; 11. does not alter clonogenic and proliferative potential of stem cells.
Numerous polymeric materials with molecularly tailored structures and surfaces are being developed for soft tissue applications in efforts to meet these 10 requirements. 53, 54 One goal is to use synthetic biomaterials to mimic the biological regulatory characteristics of natural ECMs, especially to control the microenvironment of stem cells 55 and morphogenesis. 56 Recent advances include use of self-assembled small molecular building blocks to produce nanofibrillar networks that mimic the ECM, 57 artificial ECM networks and ligandfunctionalized materials that induce response to cellsecreted signals. 58, 59 Applications include: (a) scaffold support of neural stem cells to enhance differentiation into neural cells while inhibiting development of astrocytes 59 and directing neurite outgrowth to reconstitute lost neural tissues, 60 (b) use of surface topography to control keratinocyte function and epidermal organization in artificial skin substitutes, 61 (c) modulation of the contractile and biosynthetic activity of chondrocytes in TE cartilage constructs, 62 (d) growth of microvascular blood vessels by using fibroblast growth factors to induce capillary endothelial cells to invade three-dimensional (3-D) collagen or fibrin matrices to form tubules, 63 control of the microenvironment of cells to promote natural angiogenesis for vascular repair, 64, 65 and (e) in vitro differentiation of progenitor cells to form hepatocyte-like spheroid structures with some liver-like functions.
66,67
Bioceramics provide an ideal scaffold for engineering of bone
The emphasis of our group has been to use bioactive ceramics to produce an ideal scaffold for regeneration of bone.
1,2 Bioactive glass foam scaffolds 51 meet the above criteria as they have a hierarchical porous structure with interconnected pores of 100-300 mm diameter, similar to that of trabecular bone, bond to both bone and soft connective tissues and release at controlled rates critical concentrations of biologically active silicon and calcium ions that upregulate seven families of genes in osteoprogenitor cells. 1, 2, 16 The hierarchical structure of the bioactive foams can be tailored for tissue bonding, resorption and delivery of dissolution products that provide the controlled rates of release of osteogenic stimuli, [68] [69] [70] and the nanopores can be modified with various proteins to control cell integrin-scaffold interactions. 71, 72 The calcia-silica-based materials are easily and economically processed to ISO standards 69 and have been used clinically for 20 years with FDA and CE regulatory clearance. Our studies have shown that the inorganic ionic dissolution products released during controlled resorbtion of the gel-glass scaffolds stimulate expression of genes and enhance osteogenesis in mouse and human ES cells, 16 adult human stem cells 1 and human foetal bone cells. 
A variety of materials for TE scaffolds have been assessed
There is no consensus at this time as to the best material to use in any TE application. [51] [52] [53] [54] [55] [56] [57] 62, 65, [73] [74] [75] [76] [77] [78] [79] One of the difficulties is the plethora of materials being developed and tested for use as scaffolds. Numerous biologically derived polymers include: collagen, fibrin, agarose, gelatine, alginates, hyluronan, chitosan, collagen/glycoProgress and prospects in tissue engineering J Polak and L Hench saminoglycan. Synthetic polymers include: polylactic acid (PLA), polyglycolic acid (PGA) PLA/PGA copolymers, polycaprolactone, poly(ethylene oxide), poly(vinyl alcohol), poly(acrylic acid), poly(propylene fumarateco-ethylene glycol). 73, 74 Ceramic materials include hydroxyapatite (HA), carbonate or silicon-substituted HA, various calcium phosphates and alumina. Glasses include various compositions in the SiO 2 -CaO-Na 2 O-P 2 O 5 systems. Sol-gel-derived bioactive gel-glasses and foams include a wide range of compositions in the SiO 2 -CaO-P 2 O 5 system. 68 Mixtures of many of the polymers and ceramics have been investigated in the form of biocomposites, too numerous to list. 78 The physical form of the above materials influences cell interactions; for example, cell viability depends on whether polymers are in the form of bulk, fibres, weaves, matts or hydrogels. The chemistry, surface properties, gelling conditions, stability, degradation modes and decomposition by-products differ depending on composition, surface modifications and texture. Uncertainties regarding collagen, widely used as an implant material as well as a leading candidate for TE scaffolds, illustrate the problem. The antigenic and immunogenic responses to collagen differ depending on source (usually bovine), clinical use (1-8% of patients are sensitive), implantation site, type of collagen (type I versus type II), whether the collagen is insoluble or reconstituted soluble or solubilized collagen, use of treatments to remove terminal teleopeptides (atelocollagen), extent and method of crosslinking (gluteraldehyde, etc), if any, and presence of antigenic noncollagenous proteins and cell-associated components left after processing. 79 Seldom are these factors addressed in the description and characterization of collagens used in TE papers.
A further difficulty in comparing scaffold material performance is the lack of standard tests. Cell phenotypes are seldom monitored throughout a scaffold testing programme. Most tests are carried out with established cell lines that do not represent the progenitor cells that will be present in a clinical environment. The distribution of cells in various stages of the cell cycle is not documented. Often only a few markers are analysed to determine cell viability and phenotype, and seldom are gene array studies carried out to determine the up-or downregulation of genes that are critical for obtaining and maintaining cell differentiation. Few tests are conducted such that is possible to monitor distribution of cell types throughout a 3-D construct. The anisotropy of natural tissues is rarely observed in scaffold tests. The combination of multiple cell types characteristic of tissues and organs is seldom present in tests nor is the presence of ECM, growth factors or angiogenisis. Thus, conclusions regarding effectiveness of the materials are often irrelevant to eventual clinical use.
An additional difficulty is lack of control of mechanical stimuli on cell-scaffold constructs. Morphogenesis depends on both micromechanical and microchemical gradients. The 3-D assemblages of cells within tissues comprise an intricate 3-D cytoskeletal network composed of three classes of biopolymers (microfilaments, intermediate filaments and microfilaments) that provide a continual tensile prestress (tensegrity). 80 The cytoskeleton transduces mechanical stimuli into a biochemical response. Thus, 'cells can be switched between growth, differentiation and death solely by varying the degree to which the cell physically distorts its shape'. 81 Effects of a simulated microgravity environment on TE constructs of various cell types shows the importance of micromechanical stimuli on cell differentiation and gene expression. [82] [83] [84] [85] [86] [87] Likewise, application of mechanical stimuli during growth has a large effect on the structure and mechanical properties of the resultant constructs. 88 Until highly controlled tests are conducted that encompass all of the above factors, it will be impossible to deduce which material or combination of materials is ideal for use in TE scaffolds for a given clinical objective.
Clinical application of TE strategies needs to meet a variety of challenges 
New techniques have been developed that test the efficacy of engineered tissues in vitro
Achieving and maintaining an integrated assembly of fully differentiated, mature cell phenotypes throughout the in vitro and postimplantation in vivo stages are major challenges to TE. Recent developments in two fields may help meet these objectives:
(1) New techniques have been developed for real-time monitoring of partial pressures of O 2 . 89 These may be used to provide feedback data in bioreactors in the in vitro phase of cell growth and differentiation and be used to monitor with minimal invasion of the metabolic state of TE constructs during their incorporation phase in vivo.
(2) Our groups have developed a noninvasive biophotonics system for real-time in situ monitoring of cell viability and cell death, [90] [91] [92] [93] [94] cell phenotype, 95 cell differentiation [96] [97] [98] and cellular responses to positive and negative stimuli, including severe toxins. [96] [97] [98] The bio-Raman spectroscopic cellular fingerprints obtained by this system do not require labels or markers and provide data on single or clustered cells growing in 2-D or 3-D organoids. Application of this method using fibre optic arrays to monitor TE constructs before and after implantation may overcome some of the clinical limitations of TE technology listed above. (3) Novel spectroscopic techniques have been developed to monitor structural changes in collagen fibril alignment in loaded tendons and are being applied to TE constructs. 99 In conclusion, the rapidly expanding fields of stem cell research and TE are now converging to form the new discipline of regenerative medicine, the aim of which is to restore normal function to organs and tissues that do not function properly as a result of disease, traumatic injury or birth defects. Some regenerative medicine strategies using stem cells are already in clinic, but most are still at the bench or animal testing stages. As new therapeutic approaches emerge, extensive, rigorous clinical trials must be undertaken to ensure that this very promising area of research delivers justifiable hope and not hype.
